行情

VSTM

VSTM

Verastem
NASDAQ

实时行情|Nasdaq Last Sale

1.340
+0.030
+2.29%
已收盘, 19:51 09/13 EDT
开盘
1.320
昨收
1.310
最高
1.370
最低
1.320
成交量
81.27万
成交额
--
52周最高
9.32
52周最低
1.160
市值
9,934.85万
市盈率(TTM)
-0.8729
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VSTM 新闻

  • 美国国务卿蓬佩奥谴责伊朗袭击沙特油田
  • 央视.1天前
  • 在美国腐败调查的阴影下 UAW和通用汽车接近合同期限
  • 新浪美股.1天前
  • 马斯克强调物流速度:亚马逊要像特斯拉一样早破产了
  • 新浪美股.1天前
  • 日韩交锋舞台转向WTO 日媒:对立或长期化
  • 参考消息.1天前

更多

所属板块

生物技术和医学研究
+0.20%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

VSTM 简况

Verastem, Inc., is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. It is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma.
展开

Webull提供Verastem Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。